secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001558370-24-007958
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Q1 net loss $9.8M; HOPE-3 Cohort A fully enrolled for Q4 data
----------------------------------------------------------------------

- Net loss $9.8M ($0.31/share) vs $7.8M loss prior year; revenue $4.9M from Nippon Shinyaku milestone.
- Phase 3 HOPE-3 Cohort A fully enrolled (61 patients); top-line results expected Q4 2024.
- Positive Type-B CMC FDA meeting confirmed manufacturing comparability between facilities.
- Received $10M milestone from Nippon Shinyaku; $90M pre-approval milestones remain possible.
- Cash $39.9M stable; runway into Q1 2025, excluding additional milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024007958/0001558370-24-007958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024007958/capr-20240513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer